$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
伊马替尼和格列卫有区别吗?是同一种药吗?
2025-10-19 11:44:20
Check Details
尼洛替尼医保报销新政策,尼洛替尼有比医保后更实惠的版本吗?
2025-10-19 11:44:20
Check Details
【患者关心】尼洛替尼2021年降价进展,目前尼洛替尼多少钱一盒?
2025-10-19 11:44:20
Check Details
尼洛替尼/伊马替尼/达沙替尼:慢性髓系白血病一线方案
2025-10-19 11:44:20
Check Details
尼洛替尼医保报销规则,尼洛替尼2021医保报销比例
2025-10-19 11:44:20
Check Details
白血病早期使用鲁索替尼可降低急性移植物抗宿主病的风险和严重程度
2025-10-19 11:44:20
Check Details
急性髓系白血病靶向药物吉列替尼让患者活得更久更好,吉列替尼效果怎么样?
2025-10-19 11:44:20
Check Details
哪里可以得到靶向药物吉列替尼?多少钱?
2025-10-19 11:44:20
Check Details
治疗CD33阳性患者吉妥单抗的效果更为优秀
2025-10-19 11:44:20
Check Details
唯一一款靶向CD33的AML治疗药品吉妥单抗上市竟没有选择大陆
2025-10-19 11:44:20
Check Details
格列卫2021医保后患者需自付多少钱?还有比医保后更便宜的格列卫吗?
2025-10-19 11:44:20
Check Details
医保后的格列卫解决了价格问题吗?更实惠格列卫购买点这里
2025-10-19 11:44:20
Check Details
1
2
...
626
627
628
629
630
631
632
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
2
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
3
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
4
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
5
First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20
6
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
7
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
8
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment